Related Experiment Video
Updated: May 21, 2026
08:08
Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta
Published on: June 10, 2015
Endothelin-1 and the kidney--beyond BP
Neeraj Dhaun1, David J Webb, David C Kluth
1Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK. bean.dhaun@ed.ac.uk
British Journal of Pharmacology
|June 8, 2012
Summary
Endothelin-1 (ET-1) plays a key role in chronic kidney disease (CKD) progression through both blood pressure-dependent and independent mechanisms. Its effects on cell proliferation, inflammation, and fibrosis are critical in renal disease.
Area of Science:
- Nephrology
- Endocrinology
- Molecular Biology
Background:
- Endothelin-1 (ET-1) is a peptide implicated in various physiological and pathophysiological processes.
- The role of ET-1 in chronic kidney disease (CKD) development and progression is well-established.
- ET receptor antagonists have shown efficacy in reducing blood pressure and proteinuria in CKD patients.
Purpose of the Study:
- To review the potential role of ET-1 in renal disease.
- To emphasize the blood pressure-independent actions of ET-1 in kidney disease progression.
Main Methods:
- Literature review focusing on ET-1's role in renal disease.
- Analysis of studies investigating ET-1's effects on cellular and molecular pathways in the kidney.
Main Results:
- ET-1 contributes to CKD progression through both blood pressure-dependent and independent mechanisms.
- Key independent actions include promoting cell proliferation, podocyte dysfunction, inflammation, and fibrosis.
- These BP-independent effects may be more significant in driving CKD progression than its hypertensive actions.
Conclusions:
- ET-1's multifaceted actions, particularly its BP-independent effects, are crucial in the pathogenesis of CKD.
- Targeting these independent pathways may offer novel therapeutic strategies for managing renal disease progression.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
01:17Hormonal Regulation of Blood Pressure
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
01:18Hypertension and Regulation of Blood Pressure
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...